B+
Bull case
25%
Probability
Target price
$3.00
+42.2% vs current
BTMD
bioteDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$1.90
-10.0% vs current
B-
Bear case
30%
Probability
Target price
$1.20
-43.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+40.2
Score
AI commentary
Post-earnings tone is mixed rather than outright broken: the company confirmed the print and maintained annual guidance, but the release also documented weaker revenue, margins, and first-half procedure expectations. Reliable analyst revision data was not available in the packet for this T+3 follow-up, which argues for lower conviction rather than a stronger bullish call. The packet anchor close was $2.09 on 2026-05-07, but there is not enough confirmed post-print market-reaction evidence here to claim a decisive re-rating. With low sell-side coverage, weak direct peer support, and a negative deterministic prior, this remains a cautious monitoring setup.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-05-06eventQ1 earnings showed recall-driven pressure but full-year targets were maintainedHigh impact
Biote reported Q1 2026 revenue of $44.9 million, gross margin of 68.9%, and adjusted EBITDA of $8.7 million; management said results were hit by the voluntary recall of certain hormone pellets, yet it kept 2026 guidance for revenue above $190 million and adjusted EBITDA above $38 million. This keeps the stock tied to whether recall disruption proves temporary rather than thesis-breaking. [#8-K-2026-05-06]
2026-08-15catalystSales-force build and practitioner additions need to convert into cleaner executionHigh impact
Management said newly trained practitioners and new clinic growth were improving and that the sales team was nearing its target of about 120 representatives. Near-term evidence that these commercial investments offset recall-related friction would matter because the current setup still reflects lower sales, lower gross profit, and higher operating expense pressure. [#8-K-2026-05-06]
2026-09-30catalystSecond-half procedure growth is the key recovery testHigh impact
Management said procedure revenue is expected to return to growth in the second half of 2026, while first-half procedure growth is now expected to be moderately lower than previously forecast because of product recall and supply constraints. If clinic activity and procedure volumes inflect as stated, sentiment could improve from a depressed base; if not, the maintained annual guide likely loses credibility. [#8-K-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology